In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lorus Virulizin pancreatic cancer data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Lorus Therapeutics believes its immunotherapy Virulizin could benefit a subgroup of pancreatic cancer patients with ECOG performance status of 0 or 1, the firm says Oct. 18. The Toronto biotech found, however, that its Phase III trial did not show statistical significance for median overall survival in chemo-naïve patients receiving Virulizin plus gemcitabine compared to placebo plus gemcitabine. "For the efficacy evaluable population, the study showed that the addition of Virulizin to gemcitabine resulted in a median [OS] of 6.8 months and a one-year survival rate of 27.2%, compared to 6.0 months and 16.8% for placebo plus gemcitabine," Lorus said. In ECOG PS 0/1 patients, "the result approached statistical significance with a p-value of 0.063"...

You may also be interested in...



‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding

GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.

US Government Drug Pricing ‘Negotiation:’ Where We Go From Here

The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.

Topics

UsernamePublicRestriction

Register

PS003112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel